Principal Financial Group Inc. Decreases Position in Repligen Co. (NASDAQ:RGEN)

Principal Financial Group Inc. decreased its stake in Repligen Co. (NASDAQ:RGEN) by 0.9% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 119,907 shares of the biotechnology company’s stock after selling 1,084 shares during the quarter. Principal Financial Group Inc. owned about 0.21% of Repligen worth $17,259,000 at the end of the most recent reporting period.

Several other large investors have also recently modified their holdings of RGEN. Champlain Investment Partners LLC boosted its stake in Repligen by 149.0% during the third quarter. Champlain Investment Partners LLC now owns 1,420,935 shares of the biotechnology company’s stock worth $211,464,000 after buying an additional 850,345 shares during the period. Conestoga Capital Advisors LLC lifted its holdings in shares of Repligen by 0.7% in the 4th quarter. Conestoga Capital Advisors LLC now owns 947,582 shares of the biotechnology company’s stock worth $136,395,000 after acquiring an additional 6,872 shares during the last quarter. Thrivent Financial for Lutherans boosted its stake in shares of Repligen by 6.1% during the 3rd quarter. Thrivent Financial for Lutherans now owns 638,602 shares of the biotechnology company’s stock worth $95,037,000 after purchasing an additional 36,773 shares during the period. DF Dent & Co. Inc. boosted its stake in shares of Repligen by 31.0% during the 3rd quarter. DF Dent & Co. Inc. now owns 590,321 shares of the biotechnology company’s stock worth $87,852,000 after purchasing an additional 139,615 shares during the period. Finally, New York State Common Retirement Fund grew its holdings in Repligen by 14.4% during the 3rd quarter. New York State Common Retirement Fund now owns 567,044 shares of the biotechnology company’s stock valued at $84,387,000 after purchasing an additional 71,274 shares during the last quarter. Institutional investors own 97.64% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have issued reports on RGEN shares. Wolfe Research began coverage on Repligen in a research report on Thursday, November 14th. They set a “peer perform” rating for the company. JPMorgan Chase & Co. boosted their price objective on Repligen from $190.00 to $200.00 and gave the company an “overweight” rating in a report on Friday, February 21st. Royal Bank of Canada increased their target price on Repligen from $203.00 to $205.00 and gave the stock an “outperform” rating in a research note on Friday, February 21st. StockNews.com lowered shares of Repligen from a “hold” rating to a “sell” rating in a research note on Friday, February 21st. Finally, HC Wainwright restated a “buy” rating and issued a $180.00 price target on shares of Repligen in a report on Friday, February 21st. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat, Repligen currently has an average rating of “Moderate Buy” and an average target price of $181.00.

Repligen Trading Down 2.0 %

NASDAQ RGEN opened at $161.47 on Wednesday. Repligen Co. has a one year low of $113.50 and a one year high of $203.13. The company has a debt-to-equity ratio of 0.26, a quick ratio of 8.76 and a current ratio of 10.44. The company has a market capitalization of $9.05 billion, a price-to-earnings ratio of -316.61, a price-to-earnings-growth ratio of 4.54 and a beta of 0.99. The company’s 50-day simple moving average is $155.30 and its two-hundred day simple moving average is $148.57.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings data on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.41 by $0.03. The company had revenue of $167.55 million for the quarter, compared to analyst estimates of $167.58 million. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. Equities analysts forecast that Repligen Co. will post 1.72 EPS for the current fiscal year.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.